{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:12:27Z","timestamp":1791637947070,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This subgroup analysis of the randomized, open-label, parallel-group EXCITE-HT study explored the antihypertensive efficacy and safety of esaxerenone vs trichlormethiazide in patients with type 2 diabetes mellitus (T2DM), stratified by baseline antihypertensive agent (angiotensin receptor blocker [ARB] or calcium channel blocker [CCB]) and urinary albumin-to-creatinine ratio (UACR; &lt;30 or \u226530\u2009mg\/gCr). Using thresholds consistent with those used in the main study to interpret the difference in systolic\/diastolic blood pressure (SBP\/DBP), the between-group difference in least squares mean change (95% confidence interval [CI]) in morning home SBP\/DBP at the end of treatment was \u22122.5 (\u22124.8, \u22120.2)\/\u2009\u2212\u20090.7 (\u22122.0, 0.6) mmHg. Trends were consistent across all subgroups. The geometric mean UACR significantly decreased from baseline to Week 12 in the overall population, ARB subgroup (except for esaxerenone-treated patients), CCB subgroup, and both UACR subgroups. The overall incidence of serum potassium \u22655.5 mEq\/L was 2.5% with esaxerenone and 0.9% with trichlormethiazide, with no cases of serum potassium \u22656.0 mEq\/L. In this patient population, esaxerenone had a favorable safety profile, achieved blood pressure lowering similar to trichlormethiazide, and elicited a reduction of kidney damage (based on UACR), regardless of baseline antihypertensive agent or UACR.<\/jats:p>","DOI":"10.1038\/s41440-025-02437-z","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T04:38:08Z","timestamp":1766464688000},"page":"444-456","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of esaxerenone vs trichlormethiazide for the treatment of uncontrolled essential hypertension in Japanese patients with type 2 diabetes mellitus: a subanalysis of the EXCITE-HT study"],"prefix":"10.1038","volume":"49","author":[{"given":"Mitsuru","family":"Ohishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuomi","family":"Kario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Katsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Shimosawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Shiosakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketoshi","family":"Furugori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the EXCITE-HT investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"2437_CR1","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1161\/CIRCRESAHA.118.313219","volume":"124","author":"K Kario","year":"2019","unstructured":"Kario K, Thijs L, Staessen JA. Blood pressure measurement and treatment decisions: masked and white coat hypertension. Circ Res. 2019;124:990\u20131008.","journal-title":"Circ Res"},{"key":"2437_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1001\/jamacardio.2018.1233","volume":"3","author":"T Fujiwara","year":"2018","unstructured":"Fujiwara T, Yano Y, Hoshide S, Kanegae H, Kario K. Association of cardiovascular outcomes with masked hypertension defined by home blood pressure monitoring in a Japanese General practice population. JAMA Cardiol. 2018;3:583\u201390.","journal-title":"JAMA Cardiol"},{"key":"2437_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1161\/HYPERTENSIONAHA.114.04262","volume":"64","author":"K Kario","year":"2014","unstructured":"Kario K, Saito I, Kushiro T, Teramukai S, Ishikawa Y, Mori Y, et al. Home blood pressure and cardiovascular outcomes in patients during antihypertensive therapy: primary results of HONEST, a large-scale prospective, real-world observational study. Hypertension. 2014;64:989\u201396.","journal-title":"Hypertension"},{"key":"2437_CR4","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.jacc.2016.01.037","volume":"67","author":"K Kario","year":"2016","unstructured":"Kario K, Saito I, Kushiro T, Teramukai S, Tomono Y, Okuda Y, et al. Morning home blood pressure is a strong predictor of coronary artery disease: the HONEST study. J Am Coll Cardiol. 2016;67:1519\u201327.","journal-title":"J Am Coll Cardiol"},{"key":"2437_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/HYPERTENSIONAHA.116.07201","volume":"68","author":"S Hoshide","year":"2016","unstructured":"Hoshide S, Yano Y, Haimoto H, Yamagiwa K, Uchiba K, Nagasaka S, et al. Morning and evening home blood pressure and risks of Incident stroke and coronary artery disease in the Japanese general practice population: the Japan morning surge-home blood pressure study. Hypertension. 2016;68:54\u201361.","journal-title":"Hypertension"},{"key":"2437_CR6","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1161\/HYPERTENSIONAHA.118.11388","volume":"72","author":"K Kario","year":"2018","unstructured":"Kario K, Iwashita M, Okuda Y, Sugiyama M, Saito I, Kushiro T, et al. Morning home blood pressure and cardiovascular events in Japanese hypertensive patients. Hypertension. 2018;72:854\u201361.","journal-title":"Hypertension"},{"key":"2437_CR7","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/s41440-021-00686-2","volume":"44","author":"K Narita","year":"2021","unstructured":"Narita K, Hoshide S, Kario K. Difference between morning and evening home blood pressure and cardiovascular events: the J-HOP Study (Japan Morning Surge-Home Blood Pressure). Hypertens Res. 2021;44:1597\u2013605.","journal-title":"Hypertens Res"},{"key":"2437_CR8","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41440-022-00860-0","volume":"45","author":"S Uchida","year":"2022","unstructured":"Uchida S, Kikuya M, Asayama K, Ohata C, Kimura T, Tatsumi Y, et al. Predictive power of home blood pressure in the evening compared with home blood pressure in the morning and office blood pressure before treatment and in the on-treatment follow-up period: a post hoc analysis of the HOMED-BP study. Hypertens Res. 2022;45:722\u20139.","journal-title":"Hypertens Res"},{"key":"2437_CR9","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41440-022-01136-3","volume":"46","author":"S Hata","year":"2023","unstructured":"Hata S, Ushigome E, Hosomi Y, Yoshimura T, Takegami M, Kitagawa N, et al. Impact of continued high blood pressure on the progression of diabetic nephropathy after 10 years: KAMOGAWA-HBP study. Hypertens Res. 2023;46:565\u201374.","journal-title":"Hypertens Res"},{"key":"2437_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","volume":"10","author":"MAB Khan","year":"2020","unstructured":"Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes - Global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10:107\u201311.","journal-title":"J Epidemiol Glob Health"},{"key":"2437_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.arr.2016.01.007","volume":"26","author":"TW Buford","year":"2016","unstructured":"Buford TW. Hypertension and aging. Ageing Res Rev. 2016;26:96\u2013111.","journal-title":"Ageing Res Rev"},{"key":"2437_CR12","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"2437_CR13","first-page":"575","volume":"34","author":"JR Petrie","year":"2018","unstructured":"Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34:575\u201384.","journal-title":"Can J Cardiol"},{"key":"2437_CR14","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/HYPERTENSIONAHA.123.20954","volume":"80","author":"Q Yang","year":"2023","unstructured":"Yang Q, Zheng R, Wang S, Zhu J, Li M, Wang T, et al. Systolic blood pressure control targets to prevent major cardiovascular events and death in patients with type 2 diabetes: a systematic review and network meta-analysis. Hypertension. 2023;80:1640\u201353.","journal-title":"Hypertension"},{"key":"2437_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S2213-8587(22)00172-3","volume":"10","author":"M Nazarzadeh","year":"2022","unstructured":"Nazarzadeh M, Bidel Z, Canoy D, Copland E, Bennett DA, Dehghan A, et al. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis. Lancet Diabetes Endocrinol. 2022;10:645\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2437_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","volume":"761","author":"K Arai","year":"2015","unstructured":"Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharm. 2015;761:226\u201334.","journal-title":"Eur J Pharm"},{"key":"2437_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s13318-022-00760-1","volume":"47","author":"SM Jankovi\u0107","year":"2022","unstructured":"Jankovi\u0107 SM, Jankovi\u0107 SV. Clinical pharmacokinetics and pharmacodynamics of esaxerenone, a novel mineralocorticoid receptor antagonist: a review. Eur J Drug Metab Pharmacokinet. 2022;47:291\u2013308.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2437_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","volume":"75","author":"S Ito","year":"2020","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study). Hypertension. 2020;75:51\u20138.","journal-title":"Hypertension"},{"key":"2437_CR19","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.1007\/s12325-023-02633-8","volume":"40","author":"H Motoki","year":"2023","unstructured":"Motoki H, Inobe Y, Fukui T, Iwasaki A, Hiramitsu S, Koyama S, et al. Efficacy and safety of esaxerenone in hypertensive patients with diabetes mellitus undergoing treatment with sodium-glucose cotransporter 2 inhibitors (EAGLE-DH). Adv Ther. 2023;40:5055\u201375.","journal-title":"Adv Ther"},{"key":"2437_CR20","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/s41440-019-0270-2","volume":"42","author":"H Itoh","year":"2019","unstructured":"Itoh H, Ito S, Rakugi H, Okuda Y, Nishioka S. Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study. Hypertens Res. 2019;42:1572\u201381.","journal-title":"Hypertens Res"},{"key":"2437_CR21","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.06870520","volume":"15","author":"S Ito","year":"2020","unstructured":"Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrol. 2020;15:1715\u201327.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2437_CR22","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s10157-021-02075-y","volume":"25","author":"S Ito","year":"2021","unstructured":"Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study. Clin Exp Nephrol. 2021;25:1070\u20138.","journal-title":"Clin Exp Nephrol"},{"key":"2437_CR23","doi-asserted-by":"crossref","unstructured":"Motoki H, Kuwahara K, Uchida HA, Wada J, Kario K, Katsuya T, et al. Efficacy and safety of esaxerenone with and without sodium\u2013glucose cotransporter-2 inhibitor use in hypertensive patients with type 2 diabetes mellitus: A pooled analysis of five clinical studies. Hypertens Res 2025;48:2924\u201337.","DOI":"10.1038\/s41440-025-02347-0"},{"key":"2437_CR24","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/jdi.13778","volume":"13","author":"K Shikata","year":"2022","unstructured":"Shikata K, Ito S, Kashihara N, Nangaku M, Wada T, Okuda Y, et al. Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter\u20092 inhibitor in patients with diabetic kidney disease: subanalysis of two phase\u2009III studies. J Diabetes Investig. 2022;13:1190\u2013202.","journal-title":"J Diabetes Investig"},{"key":"2437_CR25","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/jch.14705","volume":"25","author":"K Kario","year":"2023","unstructured":"Kario K, Ohishi M, Katsuya T, Taguchi T, Tanabe A, Sugimoto K, et al. Rationale and design of a multicenter randomized study comparing the efficacy and safety of esaxerenone versus trichlormethiazide in patients with uncontrolled essential hypertension: EXCITE-HT study. J Clin Hypertens. 2023;25:861\u20137.","journal-title":"J Clin Hypertens"},{"key":"2437_CR26","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/s41440-024-01762-z","volume":"47","author":"K Kario","year":"2024","unstructured":"Kario K, Ohbayashi H, Hashimoto M, Itabashi N, Kato M, Uchiyama K, et al. Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus trichlormethiazide for uncontrolled hypertension: the EXCITE-HT randomized controlled study. Hypertens Res. 2024;47:2435\u201346.","journal-title":"Hypertens Res"},{"key":"2437_CR27","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41440-024-01887-1","volume":"48","author":"K Kario","year":"2025","unstructured":"Kario K, Ohbayashi H, Hashimoto M, Itabashi N, Kato M, Uchiyama K, et al. Home blood pressure-lowering effect of esaxerenone versus trichlormethiazide for uncontrolled hypertension: a predefined subanalysis of the EXCITE-HT randomized controlled trial by basal calcium channel blocker versus angiotensin receptor blocker. Hypertens Res. 2025;48:506\u201318.","journal-title":"Hypertens Res"},{"key":"2437_CR28","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41440-024-02078-8","volume":"48","author":"K Kario","year":"2025","unstructured":"Kario K, Ohbayashi H, Hashimoto M, Itabashi N, Kato M, Uchiyama K, et al. Home blood pressure-lowering effect of esaxerenone vs trichlormethiazide for uncontrolled hypertension: a prespecified subanalysis of the EXCITE-HT randomized controlled study by age subgroup. Hypertens Res. 2025;48:1586\u201398.","journal-title":"Hypertens Res"},{"key":"2437_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41440-020-00569-y","volume":"44","author":"H Rakugi","year":"2021","unstructured":"Rakugi H, Yamakawa S, Sugimoto K. Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone. Hypertens Res. 2021;44:371\u201385.","journal-title":"Hypertens Res"},{"key":"2437_CR30","unstructured":"Esaxerenone (Minnebro) tablets [Japanese package insert]. Daiichi Sankyo Co., Ltd., Tokyo, Japan 2022. https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00070243.pdf [In Japanese]. Accessed June 23, 2025."},{"key":"2437_CR31","unstructured":"Trichlormethiazide (Fluitran) tablets [Japanese package insert]. Shionogi & Co., Ltd, Osaka, Japan 2019. https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00056852.pdf [In Japanese]. Accessed June 23, 2025."},{"key":"2437_CR32","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/hr.2013.41","volume":"36","author":"H Hasegawa","year":"2013","unstructured":"Hasegawa H, Kanozawa K, Asakura J, Takayanagi K, Komuro O, Fukada H, et al. Significance of estimated salt excretion as a possible predictor of the efficacy of concomitant angiotensin receptor blocker (ARB) and low-dose thiazide in patients with ARB resistance. Hypertens Res. 2013;36:776\u201382.","journal-title":"Hypertens Res"},{"key":"2437_CR33","doi-asserted-by":"publisher","DOI":"10.1177\/21501327211003683","volume":"12","author":"EA Christofides","year":"2021","unstructured":"Christofides EA, Desai N. Optimal early diagnosis and monitoring of diabetic kidney disease in type 2 diabetes mellitus: addressing the barriers to albuminuria testing. J Prim Care Commun Health. 2021;12:21501327211003683.","journal-title":"J Prim Care Commun Health"},{"key":"2437_CR34","first-page":"3290","volume":"21","author":"H Zhao","year":"2017","unstructured":"Zhao H, Jiang YF, Zhou XC, Yao L, Chen J, Wang D, et al. An effective indicator in predicting cardiovascular events: urine albumin to creatinine ratio. Eur Rev Med Pharm Sci. 2017;21:3290\u20135.","journal-title":"Eur Rev Med Pharm Sci"},{"key":"2437_CR35","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","volume":"9","author":"L Du","year":"2024","unstructured":"Du L, Zong Y, Li H, Wang Q, Xie L, Yang B, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:212.","journal-title":"Signal Transduct Target Ther"},{"key":"2437_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12937-023-00888-z","volume":"23","author":"Y Fan","year":"2024","unstructured":"Fan Y, Wu M, Li X, Zhao J, Shi J, Ding L, et al. Potassium levels and the risk of all-cause and cardiovascular mortality among patients with cardiovascular diseases: a meta-analysis of cohort studies. Nutr J. 2024;23:8.","journal-title":"Nutr J"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02437-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02437-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02437-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:04:36Z","timestamp":1773792276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02437-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2437"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02437-z","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Daiichi Sankyo Co., Ltd., supported all authors with medical writing and article processing charges; all authors (except for M Ohishi, T Shimosawa, K Shiosakai, T Furugori, and T Taguchi) with research funding; and M Ohishi, K Kario, T Katsuya, and T Shimosawa with advisory fees. M Ohishi received honoraria from Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., and Kowa Co., Ltd. K Kario received research grants from Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., MSD K.K., Sumitomo Pharma Co., Ltd., and Nippon Boehringer Ingelheim Co., Ltd.; consulting fees from Sanwa Kagaku Kenkyusho Co., Ltd.; honoraria from Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., and Viatris Pharmaceuticals Japan G.K.; and is an advisory board member of Daiichi Sankyo Co., Ltd. and Novartis Pharma K.K. T Katsuya received honoraria from Novartis Pharma K.K., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., AstraZeneca K.K., CureApp, Inc., Taisho Pharmaceutical Co., Ltd., and Moderna Japan Co., Ltd.; and\u00a0payment for expert testimony from CureApp, Inc. and Novartis Pharma K.K. T Shimosawa received research funding from Takenaka Co., Ltd., FUJIFILM Corp., Nippon Boehringer Ingelheim Co., Ltd., Teijin Pharma Ltd., Sumitomo Pharma Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd.; consultant fees from Sekisui Medical Co., Ltd. and EP Mediate Co., Ltd.; honoraria from Novartis Pharma K.K., Taisho Pharma Co., Ltd., Takeda Pharmaceutical Co. Ltd., Sanofi K.K., Mochida Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., AEON Co., Ltd., FUJIFILM Corp., Otsuka Pharmaceutical Co., Ltd., Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corp., Elsevier Japan K.K., Abbott Japan LLC., and Eiken Chemical Co., Ltd.; is a board member of Otsuka Medical Devices Co., Ltd. and Daiichi Sankyo Co., Ltd.; and is the chair of CVEM2023 and deputy director and educational seminars chair of the Japanese Society of Medical Use of Functional Foods, and the steering committee of the Angiotensin Gordon Research Conference. K Shiosakai, T Furugori, and T Taguchi are employees of Daiichi Sankyo Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study design and primary analysis of the EXCITE-HT study have been previously published (Kario K, et al. J Clin Hypertens (Greenwich) 2023;25:861\u20137, and Kario K, et al. Hypertens Res 2024;47:2435\u201346).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior\u00a0publication"}}]}}